Bain Capital, LP is one of the world’s leading private multi-asset alternative investment firms with approximately $105 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into several asset classes including private equity, credit, public equity, venture capital and real estate. We leverage our shared platform to capture cross-asset class opportunities in strategic areas of focus. With offices on four continents, our global team aligns our interests with those of our investors for lasting impact.

Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact [email protected].

Luca Issi, PhD

Luca Issi, PhD

Life Sciences


Luca Issi joined Bain Capital Life Sciences in 2017. Prior to joining Bain Capital, Dr. Issi worked in equity research at Cowen and Company. At Cowen, Dr. Issi was a member of the team covering the major pharmaceutical sector, where he developed financial forecasts and recommendations based on analysis of drug pipelines, clinical trials, therapeutics areas and corporate strategies. Prior to Cowen, Dr. Issi was an investment associate and content editor at BeaconVP Capital, where he performed fundamental research on small and mid-cap Biotech companies. As a scientist, Dr. Issi worked on the transcriptional circuits controlling virulence in infectious diseases.


Dr. Issi received his PhD in Biotechnology from Worcester Polytechnic Institute. He was also a collaborative researcher at the Broad Institute of Harvard and MIT and graduated summa cum laude in Biotechnology from the University of Milan (MS) and the University of Varese (BS).